CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026

By GlobeNewswire

PORTLAND, Maine, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended September 30, 2026 after the market closes on Thursday, November 12, 2026.

The Company is planning to host a conference call and webcast on November 13, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international). 

The live webcast can be accessed at: https://app.webinar.net/JL8AEda3K5D

The live webcast will feature a set of accompanying presentation slides that will subsequently be available in the Investors section of the Company’s website at: https://immucell.com/investors/ 

A teleconference replay of the conference call will be available through November 20, 2026, by dialing (855) 669-9658 (toll free) or (412) 317-0088 (international) and utilizing replay access code #2589057.

The Company anticipates no change to the preliminary sales results for the quarter ended September 30, 2026 that were disclosed on October 12, 2026. The Company expects to file its Quarterly Report on Form 10-Q on November 12, 2026 after the market closes.

About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense® line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at: http://www.immucell.com/investors.

Contacts: Olivier te Boekhorst, President and CEO
 Timothy C. Fiori, Chief Financial Officer
 ImmuCell Corporation
 investor.relations@immucell.com
  
 Joe Diaz, Robert Blum and Joe Dorame
 Lytham Partners, LLC
 iccc@lythampartners.com



Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.